Needham analyst Ami Fadia has maintained their neutral stance on ITCI stock, giving a Hold rating on February 6.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Ami Fadia’s rating is based on several factors surrounding Intra-Cellular Therapies’ recent performance and future outlook. The FDA’s acceptance of lumateperone’s supplemental New Drug Application (sNDA) for use as an adjunctive treatment in major depressive disorder (MDD) is a key development. This regulatory milestone is anticipated to have a modestly positive impact on the stock.
Ami Fadia also considered Intra-Cellular Therapies’ financial performance, noting that Caplyta achieved $199.2 million in sales during the fourth quarter, reflecting a 51% year-over-year increase and aligning with market expectations. Additionally, there is continued pipeline progress, and the anticipated closure of Johnson & Johnson’s acquisition of Intra-Cellular Therapies later this year contributes to the Hold rating, balancing both the potential upsides and uncertainties involved.
Fadia covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Merus, and Bicycle Therapeutics. According to TipRanks, Fadia has an average return of 3.4% and a 45.85% success rate on recommended stocks.
In another report released on February 6, Morgan Stanley also maintained a Hold rating on the stock with a $132.00 price target.